Table_1_Comparison of 68Ga-FAPI and 18F-FDG PET/CT for the diagnosis of primary and metastatic lesions in abdominal and pelvic malignancies: A systematic review and meta-analysis.docx

PurposeThe purpose of this study is to compare the application value of 68Ga-FAPI and 18F-FDG PET/CT in primary and metastatic lesions of abdominal and pelvic malignancies (APMs).MaterialsThe search, limited to the earliest available date of indexing through 31 July 2022, was performed on PubMed, Embase, and Cochrane Library databases using a data-specific Boolean logic search strategy. We calculated the detection rate (DR) of 68Ga-FAPI and 18F-FDG PET/CT in the primary staging and recurrence of APMs, and pooled sensitivities/specificities based on lymph nodes or distant metastases.ResultsWe analyzed 473 patients and 2775 lesions in the 13 studies. The DRs of 68Ga-FAPI and 18F-FDG PET/CT in evaluating the primary staging and recurrence of APMs were 0.98 (95% CI: 0.95-1.00), 0.76 (95% CI: 0.63-0.87), and 0.91(95% CI: 0.61-1.00), 0.56 (95% CI: 0.44-0.68), respectively. The DRs of 68Ga-FAPI and 18F-FDG PET/CT in primary gastric cancer and liver cancer were 0.99 (95% CI: 0.96-1.00), 0.97 (95% CI: 0.89-1.00) and 0.82 (95% CI: 0.59-0.97), 0.80 (95% CI: 0.52-0.98), respectively. The pooled sensitivities of 68Ga-FAPI and 18F-FDG PET/CT in lymph nodes or distant metastases were 0.717(95% CI: 0.698-0.735) and 0.525(95% CI: 0.505-0.546), and the pooled specificities were 0.891 (95% CI: 0.858-0.918) and 0.821(95% CI: 0.786-0.853), respectively.ConclusionsThis meta-analysis concluded that 68Ga-FAPI and 18F-FDG PET/CT had a high overall diagnostic performance in detecting the primary staging and lymph nodes or distant metastases of APMs, but the detection ability of 68Ga-FAPI was significantly higher than that of 18F-FDG. However, the ability of 68Ga-FAPI to diagnose lymph node metastasis is not very satisfactory, and is significantly lower than that of distant metastasis.Systematic review registrationhttps://www.crd.york.ac.uk/prospero/, identifier CRD42022332700.

本研究旨在对比68Ga-FAPI与18F-FDG PET/CT在腹部和盆腔恶性肿瘤（APMs）的原发灶和转移灶中的应用价值。研究材料包括对PubMed、Embase和Cochrane Library数据库截至2022年7月31日最早可索引日期的检索，采用特定于数据的布尔逻辑搜索策略。我们计算了68Ga-FAPI和18F-FDG PET/CT在APMs原发灶分期和复发中的检测率（DR），并基于淋巴结或远处转移汇总了灵敏度/特异性。研究结果分析了13项研究中473名患者和2775个病灶。在评估APMs的原发灶分期和复发中，68Ga-FAPI和18F-FDG PET/CT的检测率分别为0.98（95% CI: 0.95-1.00）、0.76（95% CI: 0.63-0.87）和0.91（95% CI: 0.61-1.00）、0.56（95% CI: 0.44-0.68）。在原发胃癌和肝癌中，68Ga-FAPI和18F-FDG PET/CT的检测率分别为0.99（95% CI: 0.96-1.00）、0.97（95% CI: 0.89-1.00）和0.82（95% CI: 0.59-0.97）、0.80（95% CI: 0.52-0.98）。在淋巴结或远处转移中，68Ga-FAPI和18F-FDG PET/CT的汇总灵敏度分别为0.717（95% CI: 0.698-0.735）和0.525（95% CI: 0.505-0.546），汇总特异性分别为0.891（95% CI: 0.858-0.918）和0.821（95% CI: 0.786-0.853）。结论方面，本系统评价得出结论，68Ga-FAPI和18F-FDG PET/CT在检测APMs的原发灶分期和淋巴结或远处转移方面具有高度的总体诊断性能，但68Ga-FAPI的检测能力显著高于18F-FDG。然而，68Ga-FAPI诊断淋巴结转移的能力并不令人满意，且显著低于远处转移。系统评价注册信息：https://www.crd.york.ac.uk/prospero/，标识符CRD42022332700。